The appointments reinforce the company's leadership as it progresses its first therapeutic program toward preclinical development.

The new investment will support platform expansion, preclinical development and team growth as DNAmic advances toward clinical translation.

The company showcased its human protein-based delivery platform to the international Duchenne research and patient community.

The addition of two new technical specialists strengthens DNAmic's R&D capabilities and supports the continued development of its human protein-based delivery platform.

The recognition highlights the company's scientific innovation and growing impact within the Spanish deep-tech ecosystem.